CYP3A4 isoenzyme phenotyping for personalisation of pharmacotherapy
Abstract
The article reviews existing methods of determining CYP3A4 isoenzyme activity. The authors assess the significance of CYP3A4 activity determination and the applicability of these methods in clinical practice to adjust drugs doses and minimize risks of adverse reactions. The article demonstrates the possibility of developing a method for simultaneous determination of several CYP3A4 substrates which is necessary to rule out potential errors arising upon introduction of other P450 cytochrome enzymes into metabolism of some endogenous substrate. It is suggested that blood should no longer be used as a biological object in the study in order to decrease the method’s invasiveness.
About the Authors
E. A. Egorenkov
I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
V. V. Smirnov
I. M. Sechenov First Moscow State Medical University; Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
V. N. Kuzina
I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
S. P. Dementiev
I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
G. V. Ramenskaya
I. M. Sechenov First Moscow State Medical University; Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
References
1. Denisov IG, Makris TM, Sligar SG, Schlichting I. Structure and chemistry of cytochrome P450. Chemical Reviews 2005; 105(6): 2253–77.
2. Domanski TL, He YA, Khan KK, Roussel F, Wang Q, Halpert JR. Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry 2001; 40(34): 10150–60.
3. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology and Therapeutics 2013; 138(1): 103–41.
4. Ferguson CS, Tyndale RF. Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends in Pharmacological Sciences 2011; 32(12): 708–14.
5. Qui H, Mathas M, Nestler S, Bengel C, Nem D, Godtel-Armbrust U, et al. The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability. Pharmacogenetics and Genomics 2010; 20(3): 167–78.
6. Ratajewski M, Walczak-Drzewiecka A, Sa³kowska A, Dastych J. Aflatoxins upregulate CYP3A4 mRNA expression in a process that involves the PXR transcription factor. Toxicological Letters 2011; 205(2): 146–53.
7. Ainslie GR, Wolf KK, Li Y, Wolf KK, Li Y, Connolly EA, Scarlett YV, Hull JH, Paine MF. Assessment of a candidate marker constituent predictive of a dietary substance-drug interaction: case study with grapefruit juice and CYP3A4 drug substrates. The Journal of Pharmacology and Experimental Therapeutics 2014; 351(3): 576–84.
8. De Kesel PM, Lambert WE, Stove CP. Alternative Sampling Strategies for Cytochrome P450 Phenotyping. Clin Pharmacokinet. 2016; 55(2): 169–84.
9. Elens L, Nieuweboer AJ, Clarke SJ, Charles KA, de Graan AJ, Haufroid V, van Gelder T, Mathijssen RH, van Schaik RH. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenet Genomics 2013; 23(3): 148–55.
10. Kivistö KT, Kroemer HK. Use of Probe Drugs as Predictors of Drug Metabolism in Humans. The Journal of Clinical Pharmacology 1997; 37(1 Suppl): 40–8.
11. Rivory LP, Slaviero K, Seale JP, Hoskins JM, Boyer M, Beale PJ, et al. Optimizing the erythromycin breath test for use in cancer patients. Clinical Cancer Research 2000; 6(9): 3480–5.
12. Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A, et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Journal of Clinical Pharmacy and Therapeutics 2003; 73: 517–28.
13. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, et al. Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N- acetyltransferase-2, and xanthine oxidase activities with the «Coopers-town 5 + 1 cocktail». Journal of Clinical Pharmacy and Therapeutics 2003; 74: 437–47.
14. Yin QQ, Lam SS, Lo CM, ChowMS. Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: application to cytochrome P450 phenotyping studies. Rapid Communications in Mass Spectrometry 2004; 18: 2921–33.
15. Zgheib NK, Frye RF, Tracy TS, Romkes M, Branch RA. Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Journal of Clinical Pharmacy and Therapeutics 2006; 80: 257–63.
16. Ryu JY, Song IS, Sunwoo YE, Shon JH, Liu KH, Cha IJ, et al. Development of the «Inje cocktail» for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Journal of Clinical Pharmacy and Therapeutics 2007; 82: 531–40.
17. Mirghani RA, Ericsson O, Tybring G, Gustafsson LL, Bertilsson L. Quinine 3- hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. European Journal of Clinical Pharmacology 2003; 59(1): 23–8.
18. Lin YS, Lockwood GF, Graham MA, Brian WR, Loi CM, Dobrinska MR, et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 2001; 11(9): 781–91.
19. El Desoky ES, Mohamed HO, Farghaly WM, Hamed SA, Hedaya MA, Siest JP. Study of urinary 6 beta-hydroxycortisol/cortisol ratio in spot urine sample as a biomarker of 3A4 enzyme activity in healthy and epileptic subjects of Egyptian population. Pharmacological Research 2005; 51(6): 575–80.
20. Shibasaki H, Hosoda K, Goto M, Suzuki A, Yokokawa A, Ishii K, et al. Intraindividual and interindividual variabilities in endogenous cortisol 6- hydroxylation clearance as an index for in vivo CYP3A phenotyping in humans. Drug Metab Dispos. 2013; 41(2): 475–9.
21. Shibasaki H, Kuroiwa M, Uchikura S, Tsuboyama S, Yokokawa A, Kume M, et al. Use of endogenous cortisol 6-hydroxylation clearance for phenotyping in vivo CYP3A activity in women after sequential administration of an oral contraceptive (OC) containing ethinylestradiol and levonorgestrel as weak CYP3A inhibitors. Steroids 2014; 87: 137–44.
22. De Graan AJ, Sparreboom A, de Bruijn P, de Jonge E, van der Holt B, Wiemer EAC, et al. 4-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. British Journal of clinical pharmacology 2015; 80(3): 560–8.
23. Tomalik-Scharte D, Lütjohann D, Doroshyenko O, Frank D, Jetter A, Fuhr U. Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? Clinical Pharmacology and Therapeutics 2009; 86(2): 147–53.
24. Smirnov VV. Development of methods for determining cortisol and 6-- hydroxycortisol in the urine in order to determine the activity of CYP3A4. Cand. Pharm. Sci [dissertation]. Moscow; 2011 (in Russian).
25. Smirnov VV, Savchenko AYu, Ramenskaya GV. Development and validation of methods of quantitative determination of endogenous cortisol and 6--hydroxycortisol in the urine in order to determine the activity of the isoenzyme CYP3A4. Biomeditsina 2010; 1(4): 56–60 (in Russian).
Review
For citations:
Egorenkov E.A., Smirnov V.V., Kuzina V.N., Dementiev S.P., Ramenskaya G.V. CYP3A4 isoenzyme phenotyping for personalisation of pharmacotherapy. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2017;7(1):20-24. (In Russ.)
Views:
1177
Email this article 